Page 3 - Roivant Sciences News Today

The hedge-fund manager revealed that he had built a midsized position in Penn Entertainment.

According to a lawsuit, Ramaswamy or his campaign team used pre-recorded calls to contact potential voters without obtaining their consent first.

SEOUL, South Korea, April 22, 2024 /PRNewswire/ -- OSR Holdings, a global healthcare holding company, announced that it has signed a memorandum of understanding with SillaJen, a Kosdaq-listed...

Equities Research Analysts’ updated eps estimates for Monday, April 22nd: Arch Resources (NYSE:ARCH) had its buy rating reiterated by analysts at Benchmark Co.. They currently have a $180.00 price target on the stock. Ascendis Pharma A/S (NASDAQ:ASND) had its equal weight rating reaffirmed by analysts at Morgan Stanley. They currently have a $116.00 price target […]

In this piece, we will take a look at the ten most undervalued stocks to buy that are trading under $20.

Roivant Sciences (NASDAQ:ROIV – Free Report) had its price objective increased by Deutsche Bank Aktiengesellschaft from $14.00 to $15.00 in a report released on Wednesday, Benzinga reports. They currently have a buy rating on the stock. ROIV has been the subject of several other reports. Piper Sandler started coverage on Roivant Sciences in a research […]

Roivant Sciences (NASDAQ:ROIV – Free Report) had its price target upped by HC Wainwright from $17.00 to $18.00 in a research note released on Wednesday morning, Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Roivant Sciences’ Q1 2025 earnings at ($0.25) EPS, Q2 2025 earnings […]

BioPharma

Shares of Moderna fell 4% on Wednesday after a U.S. judge issued an order that strengthened Arbutus arguments in a patent infringement lawsuit related to Modernas blockbuster COVID-19 vaccines. ...

(Reuters) -Shares of Moderna fell 4% on Wednesday after a U.S. judge issued an order that strengthened Arbutus arguments in a patent infringement lawsuit ...